Safety and preliminary efficacy of MK-0759 in postherpetic neuralgia
Phase of Trial: Phase II
Latest Information Update: 27 May 2015
At a glance
- Drugs MK 0759 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 15 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Dec 2005 New trial record.